nephrotoxicity – Medxy AI

Unlocking the Potential of Novel Biomarkers for Acute Kidney Injury in the Critically Ill: A Comprehensive Evidence Mapping

By MedXY 09/18/2026

This article reviews over 1100 studies on novel biomarkers for acute kidney injury (AKI) in critically ill patients, highlighting their predictive, diagnostic, and management roles while identifying gaps for future clinical implementation.

Infectious Diseases news

Cefazolin Is Non‑Inferior to Cloxacillin for MSSA Bacteraemia and Causes Less Kidney Injury: The CloCeBa Randomised Trial

By MedXY 11/11/2025

The CloCeBa trial found cefazolin non‑inferior to cloxacillin for meticillin‑susceptible Staphylococcus aureus (MSSA) bacteraemia, with similar 90‑day composite outcomes and substantially lower rates of serious adverse events and acute kidney injury.

Nephrology news

A‑E‑I‑O‑U and Sometimes Why—Dialysis in Acute Kidney Injury

By MedXY 11/08/2025

LIBERATE‑D randomized hemodynamically stable patients with AKI to conservative vs conventional thrice‑weekly continuation of KRT; conservative discontinuation increased dialysis‑free recovery, shortened time to recovery, and reduced sessions without detectable harm, challenging automatic thrice‑weekly schedules.